It is almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under emergency use authorization (EUA). The question still being asked is whether the vaccine is safe for people with lupus? 

A study from ACR21 convergence discussing data from the Global Rheumatology Alliance (GRA) describes the association between race/ethnicity on COVID-19 outcomes specifically in lupus patients.

At #ACR21, the plenary session included an analysis of deaths from SLE throughout the US comparing 1999 to 2019 (Abstract #0454).

On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these 15 as their favorite reports.

A treat-to-target strategy has been shown to improve clinical outcomes in patients with rheumatic diseases like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis including systemic lupus erythematosus.  The goal of treatment in SLE is aimed at remission or low disease activit